目的探讨植入磁共振兼容心脏起搏器患者行心血管磁共振(Cardiovascular Magnetic Resonance,CMR)检查的临床应用。方法纳入2020年1月至2021年12月我院10例植入磁共振兼容心脏起搏器患者为研究对象,CMR检查前以图示法进行检查流程须知宣...目的探讨植入磁共振兼容心脏起搏器患者行心血管磁共振(Cardiovascular Magnetic Resonance,CMR)检查的临床应用。方法纳入2020年1月至2021年12月我院10例植入磁共振兼容心脏起搏器患者为研究对象,CMR检查前以图示法进行检查流程须知宣教;检查过程中医生、技师、护士、工程师四方配合保证流程顺利推进,扫描间隙完成必要护理操作,以及患者心理沟通;检查后行个体化访视,记录观察指标,进行统计学分析。结果10例植入磁共振兼容心脏起搏器患者均完成CMR检查,平均耗时(45±6)min,射频能量吸收率未超过标准上限。检查前后患者心率、血压无异常改变,起搏器无异常脉冲;整体检查流程配合满意度评分(4.4±0.6)分,患者对专业知识满意度最高。结论植入磁共振兼容心脏起搏器患者行CMR检查,需制定详尽的临床观察指标与相应流程配合,以此对患者安全保证和满意度提升起到积极作用。展开更多
Video capsule endoscopy(VCE) has been applied in the last 15 years in an increasing field of applications. Although many contraindications have been put into perspective, some precautions still have to be considered. ...Video capsule endoscopy(VCE) has been applied in the last 15 years in an increasing field of applications. Although many contraindications have been put into perspective, some precautions still have to be considered. Known stenosis of the gastrointestinal tract is a clear contraindication for VCE unless surgery is already scheduled or at least has been considered as an optional treatment modality. In patients with a higher incidence of stenosis, as in an established diagnosis of Crohn's disease, clinical signs of obstruction, prior radiation or surgical small bowel resection, a preceding test with the self-dissolving patency capsule can override this contraindication. Endoscopic placement of the capsule should be considered in patients with swallowing disorders to avoid aspiration. Esophageal or gastric motility disorders may require endoscopic capsule transport or application of prokinetics if the real-time viewer proofs delayed transit. In pregnant women, VCE should be restricted to urgent cases where diagnosis cannot be postponed after delivery, as data on safety are missing. There is theoretical and clinical evidence that patients with implanted cardiac devices such as a pacemaker, cardioverters or left heart assist devices, can safely undergo VCE in spite of still existing contraindication by manufacturers. Children from the age of 2 years have safely undergone VCE. Although video capsules are not proven safe with magnetic resonance imaging(MRI), first single cases of patients incidentally undergoing MRI with an incorporated capsule have been reported, showing susceptibility artifacts but no signs of clinical harm.展开更多
目的评价植入磁共振(MRI)兼容起搏器后行1.5 T MRI扫描的安全性及起搏系统的稳定性。方法2012年1月至2015年6月于新疆医科大学第一附属医院植入MRI兼容起搏器的患者为研究对象。观察患者行MRI扫描前、扫描后即刻以及扫描后1、3、12个月...目的评价植入磁共振(MRI)兼容起搏器后行1.5 T MRI扫描的安全性及起搏系统的稳定性。方法2012年1月至2015年6月于新疆医科大学第一附属医院植入MRI兼容起搏器的患者为研究对象。观察患者行MRI扫描前、扫描后即刻以及扫描后1、3、12个月的起搏器系统稳定性及起搏阈值、感知、阻抗和电池寿命及临床不良事件。结果113例患者接受MRI扫描并按时完成各阶段随访,扫描过程中无心前区不适感、无误感知、无脉冲发生器重置、无起搏器导线脱位,除1例阵发性心房颤动(房颤)患者扫描中监测到房颤外其余患者未监测到心律失常。患者心房起搏阈值、感知,心室起搏阈值、感知在MRI扫描后各随访时间点与扫描前变化无临床意义。1例患者MRI扫描后12个月发生下壁心肌梗死,心室感知幅度较基线下降50%以上,其余患者随访未发现起搏阈值增加0.5 V以上、感知下降50%以上以及起搏器电池提前耗竭情况。心室导线阻抗MRI扫描后12个月与基线对比差异有统计学意义[(530.10±117.87)Ω对(547.76±122.00)Ω,P=0.001],随访期间无心房导线、心室导线阻抗<200Ω或>1500Ω。结论植入MRI兼容起搏器患者进行1.5 T MRI扫描时患者无不良事件发生,安全性好。展开更多
文摘目的探讨植入磁共振兼容心脏起搏器患者行心血管磁共振(Cardiovascular Magnetic Resonance,CMR)检查的临床应用。方法纳入2020年1月至2021年12月我院10例植入磁共振兼容心脏起搏器患者为研究对象,CMR检查前以图示法进行检查流程须知宣教;检查过程中医生、技师、护士、工程师四方配合保证流程顺利推进,扫描间隙完成必要护理操作,以及患者心理沟通;检查后行个体化访视,记录观察指标,进行统计学分析。结果10例植入磁共振兼容心脏起搏器患者均完成CMR检查,平均耗时(45±6)min,射频能量吸收率未超过标准上限。检查前后患者心率、血压无异常改变,起搏器无异常脉冲;整体检查流程配合满意度评分(4.4±0.6)分,患者对专业知识满意度最高。结论植入磁共振兼容心脏起搏器患者行CMR检查,需制定详尽的临床观察指标与相应流程配合,以此对患者安全保证和满意度提升起到积极作用。
文摘Video capsule endoscopy(VCE) has been applied in the last 15 years in an increasing field of applications. Although many contraindications have been put into perspective, some precautions still have to be considered. Known stenosis of the gastrointestinal tract is a clear contraindication for VCE unless surgery is already scheduled or at least has been considered as an optional treatment modality. In patients with a higher incidence of stenosis, as in an established diagnosis of Crohn's disease, clinical signs of obstruction, prior radiation or surgical small bowel resection, a preceding test with the self-dissolving patency capsule can override this contraindication. Endoscopic placement of the capsule should be considered in patients with swallowing disorders to avoid aspiration. Esophageal or gastric motility disorders may require endoscopic capsule transport or application of prokinetics if the real-time viewer proofs delayed transit. In pregnant women, VCE should be restricted to urgent cases where diagnosis cannot be postponed after delivery, as data on safety are missing. There is theoretical and clinical evidence that patients with implanted cardiac devices such as a pacemaker, cardioverters or left heart assist devices, can safely undergo VCE in spite of still existing contraindication by manufacturers. Children from the age of 2 years have safely undergone VCE. Although video capsules are not proven safe with magnetic resonance imaging(MRI), first single cases of patients incidentally undergoing MRI with an incorporated capsule have been reported, showing susceptibility artifacts but no signs of clinical harm.
文摘目的了解无导线起搏器临床应用的安全性和稳定性,评估术后行3.0 T磁共振成像(MRI)的安全性和可行性。方法本研究为单中心回顾性研究,入选2015年2月至3月和2018年7月至11月在阜外医院植入无导线起搏器(Micra TPS)的患者,分别在出院前,植入后1、3、12、24、36、48、60个月进行随访,收集起搏电学参数和不良事件;部分患者术后3个月接受3.0 T MRI扫描并定期随访。结果共入选患者20例,年龄(64.0±11.1)岁,男12例(12/20,60%)。19例患者成功植入无导线起搏器,手术成功率为95.0%(19/20);术中电学参数均在理想范围内:起搏阈值为(0.52±0.18)V/0.24 ms,导线阻抗为(839.0±234.6)Ω,R波感知为(10.4±4.0)mV,围术期无严重不良事件。5例患者术后3个月接受了3.0 T心脏或头颅MRI扫描,并随访至扫描后21个月,电学参数均稳定。平均随访(33.0±15.6)个月,其中4例患者完成术后60个月随访;随访期间导线阻抗、起搏阈值、R波感知等电学参数均稳定,无并发症发生,1例患者术后51个月因恶性肿瘤死亡。结论无导线起搏器(Micra TPS)具有良好的安全性和稳定性,术后进行3.0 T MRI扫描是安全的。无导线起搏器为单腔起搏器适应证患者提供了新选择,具有广阔的应用前景。
文摘目的评价植入磁共振(MRI)兼容起搏器后行1.5 T MRI扫描的安全性及起搏系统的稳定性。方法2012年1月至2015年6月于新疆医科大学第一附属医院植入MRI兼容起搏器的患者为研究对象。观察患者行MRI扫描前、扫描后即刻以及扫描后1、3、12个月的起搏器系统稳定性及起搏阈值、感知、阻抗和电池寿命及临床不良事件。结果113例患者接受MRI扫描并按时完成各阶段随访,扫描过程中无心前区不适感、无误感知、无脉冲发生器重置、无起搏器导线脱位,除1例阵发性心房颤动(房颤)患者扫描中监测到房颤外其余患者未监测到心律失常。患者心房起搏阈值、感知,心室起搏阈值、感知在MRI扫描后各随访时间点与扫描前变化无临床意义。1例患者MRI扫描后12个月发生下壁心肌梗死,心室感知幅度较基线下降50%以上,其余患者随访未发现起搏阈值增加0.5 V以上、感知下降50%以上以及起搏器电池提前耗竭情况。心室导线阻抗MRI扫描后12个月与基线对比差异有统计学意义[(530.10±117.87)Ω对(547.76±122.00)Ω,P=0.001],随访期间无心房导线、心室导线阻抗<200Ω或>1500Ω。结论植入MRI兼容起搏器患者进行1.5 T MRI扫描时患者无不良事件发生,安全性好。
